Background: Stereotactic radiotherapy (SRT) is a safe and locally effective treatment for patients with inoperable oligometastases. The challenge remains identifying subsets of patients that benefit in terms of overall survival (OS).
introduction
For many years, the diagnosis of metastatic cancer was considered a fatal illness. In 1995, Hellman and Weichselbaum [1] hypothesized the existence of oligometastases; a clinical disease state where tumors early in the evolution of metastatic progression produce metastases which are limited in number and location. Biological data support the long-standing presumption of a potential temporal evolution with an intermediate stage of restricted metastatic capacity, where oligometastatic tumors may not have acquired the broad array of genetic changes to develop widespread metastases [2, 3] . In 2%-3% of all cancers, recent genome analyses in contrast suggest an alternative process that involves massive de novo structural rearrangement formation in a one-step catastrophic genomic event coined chromothripsis [4] . This phenomenon is associated with poor survival and considered a feature of some aggressive cancer forms [5] .
Retrospective studies provide evidence that eradication of oligometastases by complete metastasectomy offers a chance for long-term survival in selected patients [6, 7] . Limitations imposed by localization, multifocality, size and comorbidities exclude most of oligometastatic cancer patients from undergoing metastasectomy. Radiofrequency ablation and stereotactic radiotherapy (SRT) are valuable alternatives for these patients [8] [9] [10] .
In the UZ Brussel patients with a Karnofsky Performance Status of more than 70 and no more than 5 metastases are treated by SRT since 2005, according institutional guidelines. In phase I/II trials, stereotactic body radiotherapy displayed 2-to 3-year survival rates in the range of 30%-64% [11] [12] [13] . The challenge remains identifying the role of SRT in the treatment algorithm of oligometastatic cancer. To do so, randomized phase III trials evaluating the addition of SRT to chemotherapy are mandatory. The aim of the current study is identifying subsets of oligometastatic cancer patients with good prognosis that are candidates for inclusion in such trials. Therefore, the outcome of 309 patients after SRT was analyzed and a risk factor analysis was carried out.
patients and methods

patient selection
We performed a retrospective analysis of patients who presented five or fewer metastases at any site and who were referred for SRT between 2005 † TdV and BE contributed equally to this study. *Correspondence to: Prof. Mark De Ridder, Department of Radiation Oncology, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium. Tel: +32-2-477-61-44; Fax: +32-2-477-62-12; E-mail: mark.deridder@uzbrussel.be and 2011. Primary tumors were required to be treated curatively and considered inactive/controlled. Synchronous metastases were defined as metastases occurring within 1 month of diagnosis of the primary tumor. Whole-body computed tomography (CT) was carried out in all patients to identify and discern metastatic lesions. Unless contraindicated, all patients with brain metastases underwent magnetic resonance imaging (MRI). To be noticed, 82% of the patients underwent fluorodeoxyglucose-positron emission tomography (FDG-PET) for staging before the indication of SRT was made. All metabolically active, grossly viable metastatic diseases were required to be treated. Clinical records of 309 oligometastatic cancer patients were retrospectively reviewed. Pathological information was described according to the American Joint Committee on Cancer (AJCC) 7th edition.
treatment schedules
In total, 580 metastases were treated, of which 430 extracranial lesions and 150 intracranial lesions. Fractionation schedules are displayed in supplementary Table S1 available at Annals of Oncology online. Briefly, those applied for extracranial metastases consisted generally of a total dose of 40-50 Gy in 10 daily fractions. Less frequently applied fractionation schedules were 36 Gy in three 12-Gy fractions; 42.5 Gy in five 8.5-Gy fractions and 30 Gy in three 10-Gy fractions. Brain metastases were generally treated either with a single 20-Gy fraction or with five 6-Gy or 7-Gy fractions according to location and diameter. The biologically effective dose (BED) was calculated to enable a homogenous evaluation. Assuming the α/β ratio to be 10, the median delivered BED (BED 10 ) for the whole patient population was 60 (range, 26-112) Gy. Intracranial metastases were mainly treated with a BED 10 of 60 Gy (83%) and 48 Gy (8%); the median BED 10 was 60 (range, 26-88) Gy. The median BED 10 for lymph node, liver, lung and bone metastases was 59 (range, 47-108), 56 (range, 45-112), 75 (range, 56-120) and 56 (range, 39-75) Gy, respectively.
radiotherapy technique
All patients in this study were treated with dedicated machines. Those with intracranial metastases (n = 107) were treated by the Novalis system, mostly in a single fraction of 20 Gy ( prescribed at 80% isodose) or, for lesions >3 cm, in five fractions of 7 Gy. Patients with extracranial metastases were treated by Novalis (n = 89) or the TomoTherapy Hi Art II system (n = 120), with dose prescription following the ICRU Report 62 guidelines. The planning goal was to deliver at least 95% of the prescribed dose to at least 95% of the planning target volume.
statistical analysis
Survival from the first day of SRT to death or last date of follow-up was analyzed using data obtained from clinical follow-up and from the Belgian National Cancer Registry. The prognostic impact of the following variables was assessed: age, gender, histology of the primary tumor at diagnosis, latency time (time between the diagnosis of the primary tumor and first occurrence of metastasis), metastatic location, gross tumor volume (GTV), number of metastatic lesions, number of involved organ sites and BED. Univariate analysis (UVA) for survival was estimated by the Kaplan-Meier test; the differences among the groups were analyzed by the log-rank test. Statistically significant factors in the UVA were entered into the multivariate analysis (MVA), which was carried out by a Cox proportional hazards model. A P-value of ≤0.05 was considered to be statistically significant. In addition, we estimated local control (LC), distant control (DC) and progression-free survival (PFS) by Kaplan-Meier analysis. SPSS 21.0 software was used for all statistical analyses. results
patient characteristics
Patient and tumor characteristics are detailed in Table 1 . The median age of the patient population was 63 years (range, 37-91 years). Histological types were adenocarcinoma in 73% and nonadenocarcinoma in 23%, with squamous cell carcinoma as the most common histology in nonadenocarcinoma patients. The most frequent primary tumors were colorectal cancer (33%), lung cancer (33%) and breast cancer (11%). One hundred fifteen patients (37%) presented with synchronous oligometastatic disease. Most patients had one to three metastatic lesions and one to three involved oligometastatic sites. The main sites were the brain (35%), lymph nodes (29%), liver (25%), lung (18%), bone (8%) and adrenal gland (5%). The median GTV per patient was 14.5 ml (range, 0.08-644 ml).
survival and risk factor analysis
At time of analysis, 204 patients (66%) had died. The median follow-up for the surviving patients was 12 (range 1-84) months. The median survival time (MST) of all patients was 24 months (supplementary Figure S1 available at Annals of Oncology online). The 3-, 4-and 5-year OS rates were 32%, 25% and 19%, respectively. Male, synchronous oligometastatic disease, latency time of <12 months, delivered BED 10 <75 Gy, intracranial, extranodal metastatic disease and nonadenocarcinoma histology were associated with significantly impaired median survival in UVA (supplementary Table S2 available at Annals of Oncology online). Age, GTV, number of oligometastatic lesions and number of oligometastatic sites were not significant in UVA. However, when excluding patients with intracranial metastases, UVA showed that OS was significantly influenced by the number of metastases (P = 0.022). Patients with a solitary extracranial metastasis achieved a MST of 40 months, whereas patients with 2-5 extracranial metastases achieved a MST of 26 months. The significant variables on UVA were tested with MVA using a Cox proportional hazards regression model (Table 2) . We could define four patientinherent factors in our patient population that were independently associated with impaired OS: nonadenocarcinoma histology, intracranial oligometastatic disease, synchronous occurrence of oligometastases and male gender (supplementary Figure S2 available at Annals of Oncology online). A BED 10 <75 Gy remained associated with significantly impaired OS on MVA as well (P = 0.02), but was considered a patient's noninherent factor.
In order to identify the subset of oligometastatic cancer patients that may benefit maximally from SRT, patients were subdivided into five groups according to their number of poor prognostic patient-inherent factors (0-4) as described in the MVA (Figure 1) . Fifty-two patients presented without any risk factor and achieved a MST of 40 months [95% confidence interval (CI) 24-63]. One, 2, 3 and all 4 risk factors were seen in, respectively, 101 (MST of 29 months; 95% CI 23-35), 95 (MST of 23 months, 95% CI 16-29), 42 (MST of 9 months, 95% CI 6-11) and 6 patients (MST of 4 months, 95% CI 1-7).
Lastly, LC, DC and PFS could be assessed in 214 patients (69%). We calculated a median LC of 11 months (95% CI 7-15) and a 2-year LC rate of 33% (95% CI 25-40). Interestingly, a BED 10 ≥75 Gy was correlated with a significant increase in original articles Annals of Oncology median time to local recurrence (18 versus 10 months for BED 10 <75 Gy, P = 0.02). The 2-year DC and PFS rates were 20% (95% CI 15-26) and 10% (95% CI 6-16), respectively. Patients with extracranial metastases displayed significantly superior 2-year PFS compared with those with intracranial metastases (16% versus 3%, P = 0.002).
discussion
We report the outcome of 309 oligometastatic cancer patients that were treated by SRT, the largest retrospective series to our knowledge. The MST of 24 months and 4-year OS rate of 25% (95% CI 19-32) reflects the potential long-term survival and is in concordance with the data by Milano et al. [14] , who reported a 4-year OS rate of 28% in 121 patients. It remains unclear whether this hopeful survival reflects a selection of cancers with limited metastatic potential, or whether it is partly due to the effect SRT. Randomized trials comparing standard chemotherapy with or without SRT are essential to determine the role of radiotherapy in oligometastatic cancer.
MVA indicated that nonadenocarcinoma histology was associated with significantly worse OS, with a median survival of only 6, 9 and 13 months for patients with melanomas, small-cell No, number; GTV, gross tumor volume; BED, biologically effective dose; Gy, gray. 
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lung cancers and squamous cell carcinomas, as opposed to a median survival of 27 months for patients with adenocarcinomas. Similarly, Rusthoven et al. [15] reported better survival in patients treated with SRT for liver metastases from so-called favorable primary tumors, predominantly colorectal and breast adenocarcinomas. Regarding location, 107 patients (35%) presented in this study intracranial oligometastases and achieved a MST of 11 months only, which was significantly lower compared with patients displaying extracranial disease only (MST of 28 months). Brain metastases often occur secondary to extracranially located metastatic lesions and are thus associated with later stages of metastatic progression [16] . Moreover, they become more rapidly symptomatic and life-threatening because of the brain's rigid encasement, its relatively small size compared with other body cavities and its high sensitivity to increased intracranial pressure [17] . Sanghavi et al. [18] retrospectively pooled 502 patients with brain metastases from SRT databases of 10 institutions and reported a similar MST of 10.7 months. The role of SRT remains pivotal in the management of brain metastases to reduce the neurologic symptoms and because more than half of these patients die of intracranial progression [19] . For patients undergoing surgical resection for liver and lung metastases, a short disease-free interval from the primary tumor to first occurrence of metastases is being considered as a poor prognostic factor [20, 21] . Since the metastatic tumor clone arises from the primary tumor, Weichselbaum and Hellman [22] addressed the importance of control of the primary tumor when eradicating 'early' oligometastases. The status of the primary tumor (treated with curative intent or not) was proposed by Niibe et al. [23] as the most important prognostic factor of OS for oligometastatic cancer patients. Patients with synchronous oligometastases at diagnosis in our study exhibited worse OS in comparison to those with metachronous oligometastases (MST of 18 versus 26 months), but we should mention here that all patients with synchronous oligometastatic disease also underwent a radical treatment of the primary tumor. We believe that a subset of synchronous oligometastatic patients, with a controlled primary site, could still benefit from a radical treatment as is reported for NSCLC [24] . How female gender favors oligometastatic cancer survival has to be clarified. However, the prognostic value of sex is not surprising as this has been reported previously for metastatic esophageal [25] and CRC [26] , as well as for cutaneous melanoma [27] . Hormonal factors and sex differences in immunity, molecular basis and natural disease course have been suggested to serve as explanation.
Concerning the heterogeneity in dose regimens in the current study, we obtained a homogenous evaluation by reporting on the BED. The delivered BED in our patient population is lower compared with the SRT dose regimens applied in recent prospective studies. The strict inclusion criteria in those studies for the delivery of BED >100 Gy should however be mentioned. In our institution, we aimed at a broad applicability of SRT to oligometastatic cancer patients, including those with large and/or critically located metastases. In these circumstances, a BED >100 Gy can often not be delivered without violation of the dose-volume constraints of the surrounding healthy tissues. Furthermore, regimens resulting in a BED >100 Gy are considered to be ablative, but no definition of the doses needed for ablative radiotherapy is universally accepted yet. In a review on SRT for oligometastases, Tree et al. [28] suggested that a BED of 75 Gy might be sufficient to eradicate viable tumor cells by referring to the schedule of 50 Gy in 5-Gy fractions which has been successfully applied for extracranial oligometastases in different sites [14] . Interestingly, a BED 10 ≥75 Gy was found to be correlated with a statistically significant superior OS on UVA (P < 0.01) and MVA (P = 0.02). As a consequence of the moderate delivered BED in the current study, the reported LC rates are lower when compared with those in prospective SRT series. Of notice, a BED 10 ≥75 Gy was correlated with a better LC by increasing the median time to local recurrence by 8 months.
Tumor burden, determined by metastatic size and number, is generally presumed to influence outcome. In the current study, neither the size nor the number (1-5) of the treated oligometastases appeared to be prognostic for survival. After exclusion of patients with intracranial metastases from the whole-population group, UVA revealed that the number of metastases (1 versus 2-5) did predict outcome in this particular subgroup (P = 0.02). To date, it remains unclear whether the number of metastases (1) (2) (3) (4) (5) is an important determinant of survival, as been previously claimed [29] and denied [14, 30, 31] by several authors.
An important limitation of the current study is the patient heterogeneity. We reported on the outcome of a large number of oligometastatic patients by not restricting the patient population to a specific subset, which might be a concern for the extraction of statistically significant prognostic indicators. Although not providing definite answers in terms of outcome for a particular disease site, we could propose a prognostic model based on the four independent clinical risk factors of the MVA; nonadenocarcinoma histology, intracranial metastases, synchronous oligometastatic disease and male gender. Patients with 0-2 risk factors displayed a median survival of 23-40 months and are defined as patients with good prognosis. Patients with 3 and 4 risk factors had a median survival of 4-9 months only and are defined as bad prognostic patients. As a next step, we want to evaluate the efficacy of SRT as consolidation after chemotherapy for patients with oligometastatic cancer in a prospective randomized trial. Essentially, patients from the good prognostic group will receive 4-6 months of chemotherapy. Patients with a response or stable disease will be randomized between follow-up original articles Annals of Oncology and SRT. The primary end point will be time to reintroduction of systemic treatment (drug-free interval). Secondary end points will be quality of life, toxicity, PFS, overall survival, LC and costbenefit. This trial might identify a subset of oligometastatic cancer patients that are curable with SRT [13] . 
